Our R&D Approach

Our research mission is simple: innovations that improve the quality of life of people everywhere. That motivation keeps us at the forefront of the Healthcare, Life Science and Performance Materials industries.


Healthcare R&D

Our research scientists are hard at work on groundbreaking medicines and technologies to treat everything from cancer, multiple sclerosis to infertility. Wherever there is a medical need, our highly experienced research and development team hopes to meet it. Learn more

Biopharmaceuticals

Biopharmaceuticals

Life Science R&D

R&D focus: Reimagining new ways to meet the needs of our customers

Innovation is at the core of the value that we deliver to our customers. Our Life Science business is research driven and innovation focused. In 2016, we invested 260 million Euro in R&D which supported our innovation in launching 2,100 products – products designed to meet our customers' most unmet needs – from antibodies to water purification systems.

The ability to innovate is the core of our culture across all three of our businesses; Research Solutions, Process Solutions and Applied Solutions. Learn more

Performance Materials R&D

R&D focus: Keeping the world’s performance materials on the cutting edge

Our performance materials business is an innovation leader, constantly producing new technologies and new markets for our customers, often through partnerships across industries. We have come up with groundbreaking liquid crystal displays and windows, effect pigments for coatings and color cosmetics and high-tech materials for use in integrated circuits. Learn more

Related News

View All News
  1. Press Releases

    BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New ...

    Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono, Inc. in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced the publication of detailed results from the..

    2020/09/18

  2. Press Releases

    FDA Accepts Filing of New Drug Application for Tepotinib for the Treatment ...

    Merck KGaA, Darmstadt, Germany, today announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review to the new drug application (NDA) for once-daily, orally-dosed tepotinib*

    2020/08/25

  3. Press Releases

    NICE Recommends BAVENCIO® (Avelumab) in Combination with Axitinib ...

    This is the first combination of an immunotherapy with a targeted antiangiogenic therapy to be recommended by NICE as a first-line treatment option for aRCC for use within the Cancer Drugs Fund.

    2020/07/31

Healthcare R&D

Our research scientists are hard at work on groundbreaking medicines and technologies to treat everything from cancer, multiple sclerosis and infertility to colds and pains. Wherever there is a medical need, our highly experienced research and development team hopes to meet it. Learn more

Redirect

You have accessed https://www.emdgroup.com, but for users from your part of the world, we originally designed the following web presence https://www.merckgroup.com.

Let's go

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement